Consequently, both prevalent and rare metabolic diseases associated with increased intrahepatic glucose availability, such as type 2 diabetes and Glycogen Storage Disease type 1 (GSD I), are characterized by enhanced ChREBP activity in the liver [[5], [6], [7], [8], [9]]. The gene discussed is MLXIPL; the disease is metabolic disease.